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ABSTRACT
Ferric chelates may be used as oral iron supplements or phosphate binders but 
both ferric citrate and ferric EDTA have been shown to promote tumor burden in 
murine models of colon cancer. Here we studied their effects on cancer cell growth, 
at typical supplemental iron levels encountered in the gastrointestinal tract (0.01-0.2 
mM). Caco-2 and/or Hutu-80 cells were exposed to these forms of chelated iron or to 
ferrous sulfate and outcomes were assessed using cell proliferation assays, proteome 
profiler arrays, western blot, and ELISA. Ferric EDTA and ferric citrate increased 
cellular levels of the onco-protein amphiregulin and its receptor (EGFr) which in turn 
stimulated the activation of the MAP kinase ERK. Simultaneously, the expression of the 
negative Wnt regulator, DKK-1, increased suggesting that cell proliferation through 
the Wnt pathway may be less pronounced in the presence of ferric EDTA and ferric 
citrate, unlike for ferrous sulfate. Moreover, ferrous sulfate did not increase levels of 
cellular amphiregulin or EGFr. We conclude that specific iron compounds affect cell 
signaling differently and some may increase the risk of colon cancer advancement in 
an amphiregulin-dependent fashion. Further scrutiny of safe oral iron use is merited.
INTRODUCTION
Different chemical forms of oral iron are widely 
used in the prevention and treatment of iron deficiency 
anemia [1] and some may also be used as ‘phosphate 
binders’ to control dietary phosphate absorption in patients 
with renal disease [2, 3]. However, certain of these, 
notably two different ferric iron chelates, ferric EDTA and 
ferric citrate, have been observed to promote colon cancer 
in mice [4–7]. In one study, oral administration of ferric 
EDTA drove ulcerative colitis-associated carcinogenesis 
in two murine models, namely DSS-induced colitis and 
interleukin-2 knockouts. These findings were in contrast 
to low-dose intraperitoneal injections of iron-dextran (6 or 
12 mg/kg body weight) which did not significantly affect 
tumor incidence or number, indicating that it is not body 
iron status per se that exacerbates colon cancer growth. 
In another study, using the DSS model again, long-term 
oral administration of ferric EDTA, at the same level as 
background dietary iron (i.e. + 49 mg Fe/kg diet thereby 
doubling total Fe intake), markedly increased tumor 
incidence compared to controls or mice receiving i.v. iron 
[2]. The obvious conclusion for the differential effects 
of oral and parenteral iron is that oral iron temporarily 
accumulates in the colon, where transit times are relatively 
slow, and if it is bioavailable, then this may promote local 
cancer growth, oxidative stress, and DNA damage [8].
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However, whether the carcinogenic effects observed 
in vivo are restricted to certain forms of chelated iron 
or, in fact, extend to soluble forms of iron per se is not 
clear. Indeed, iron uptake by colorectal cancers has been 
shown to be achieved through local upregulation of the 
iron transport protein, DMT1 and the ferric reductase 
DcytB [9], and so it could be the case that any iron that 
is a substrate for this transporter risks exacerbating colon 
cancer. At low concentrations, ferrous ions tend not to 
precipitate and are thus bioavailable, especially to DMT-
1. Indeed, it is generally considered that iron from ferrous 
sulfate is more bioavailable than from ferric citrate or 
ferric EDTA although iron bioavailability is dependent 
upon the diet composition such that a diet rich in phytate 
might inhibit iron absorption from ferrous sulfate but less 
so from ferric EDTA [10] Indeed, based upon in vitro 
data, a case could be made for ferrous sulfate, as well 
as some forms of chelated iron, for aggravating large 
bowel cancer risk. In this respect, a common mutation 
in colorectal cancers involves the tumor suppressor 
adenomatous polyposis coli (APC) gene. Loss of the APC 
gene product leads to accumulation of nuclear β-catenin 
which activates Wnt target genes involved in promoting 
cell proliferation and tissue growth (reviewed in [11, 12]). 
Several cell models (e.g. Caco-2, Hutu-80, SW480) used 
in gut research have mutations affecting β-catenin/Wnt 
signaling pathways. Incubation studies lasting twenty-
four hours with Caco-2 or SW480 cells have shown Wnt 
signaling to be up-regulated by 0.1 mM ferrous sulfate, as 
well as by the chelate hemin at 0.05 mM [5, 13, 14]. On 
the other hand, whilst, for the SW480 cell line, Xue et al 
report increases in expression of the STAT3 protein and 
phosphorylated STAT3, in response to 0.01 and 0.1 mM 
ferrous sulfate, Wnt signaling was not increased [15].
In summary, it is not understood whether all 
forms of ‘bioavailable’ iron exacerbate gut cancer 
cells, and if so, if the same mechanism is involved for 
different such iron forms. We studied these questions at 
the cellular level using ferric citrate, ferric EDTA and 
ferrous sulfate.
RESULTS
Amphiregulin is induced in response to ferric 
citrate and ferric EDTA
First, targeted antibody arrays (proteome profiler™ 
arrays) were used to detect cancer-related protein levels 
on pooled triplicates of Caco-2 or Hutu-80 cells incubated 
with high concentrations (0.5-2 mM) of ferric citrate, 
which approximates to an equivalent 150-600 mg oral 
iron dose in a human subject (see Methods) as might 
be used for dietary phosphate binding in renal patients 
[3]. Notably, this induced cell-associated amphiregulin 
protein compared to controls (Figure 1A). Amphiregulin 
is a soluble paracrine growth factor and a ligand of the 
epidermal growth factor receptor (EGFr) (Supplementary 
Figure 1). Its major role is to promote proliferation 
and inhibit apoptosis during normal physiological 
developmental phases but abnormal induction has been 
implicated in epithelial cancers such as breast, ovary, lung, 
and colorectal cancers and is associated with activation 
of map kinases [16]. In addition, the levels of the 
amphiregulin target (EGFr) and the Wnt inhibitor DKK-1 
were also increased in the presence of ferric citrate. Ferric 
EDTA at 0.5 mM also induced Amphiregulin, EGFr, and 
DKK-1 proteins whereas ferrous sulfate had no such effect 
(Figure 1B and 1C). Interestingly, Ferric citrate and ferric 
EDTA, but not ferrous sulfate, elevated protein levels of 
amphiregulin and DKK-1, even at low supplemental iron 
levels (0.05 mM) which would equate to an oral dose 
of 15 mg in humans (Figure 1E). However, at these low 
doses, the amphiregulin target, EGFr, was unaltered by 
all treatments (Figure 1E). In independent experiments, 
direct quantative data of cellular amphiregulin levels, in 
response to ferric citrate, ferric EDTA, and ferrous sulfate, 
supported the semi-quant proteome profiler data Figure 2.
Elevated levels of amphiregulin are not related 
to cellular exposure to iron per se
One facile explanation for the results above is that 
the different forms of iron have different efficiencies 
of iron delivery to the cell and that this dictates the 
amphiregulin responses observed. We considered two 
separate angles. Firstly, the direct loading of cells by 
iron, in particular using the iron storage form, ferritin, 
as a read out for true intracellular iron targeting because 
measuring cell-iron content, grossly, does not distinguish 
cell-membrane-bound-iron from intracellular iron (i.e. 
it measures all cell-associated iron). Secondly, we 
considered how, at the molecular level, intracellular iron 
concentration might directly determine amphiregulin 
abundance.
We compared amphiregulin levels at low iron 
exposure (0.05 mM) and the corresponding intracellular 
ferritin formation. In these cells, and as expected, 
amphiregulin was affected by the chelates used (iron in 
citrate or EDTA form) but not by ferrous sulfate. However, 
the increase in ferritin levels after iron exposure from 
the chelates did not follow the same trend as changes to 
amphiregulin (Figure 1E versus Figure 3A). Indeed, with 
low dose of iron supplementation the order of ferritin 
formation (iron bioavailability) was as follows: ferric 
citrate > ferric sulfate > ferric EDTA (Figure 3A), so this 
did not explain amphiregulin upregulation by the chelated 
iron forms only. To exclude the possibility that ferritin 
expression was induced by other signaling pathways, we 
compared the total iron content of cells incubated with 
high dose ferric citrate or ferrous sulfate (2 mM) with 
their ferritin levels. The ratio of iron:ferritin was similar 
for both iron forms, showing that ferritin levels were 
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Figure 1: Proteome profiler™ arrays on human epithelial colorectal adenocarcinoma Caco-2 cells incubated with 
different iron compounds. The cells were incubated with (A) Ferric citrate (0.5 mM), (B) Ferrous sulfate (0.5 mM), (C) Ferric EDTA 
(0.5 mM). Red box= Amphiregulin, Black box = EGFr, Green box= DKK-1, Blue box= Progranulin. (D) Quantative data based on the 
arrays (n=3). Fold changes ≥2 and signal ≥10% of the internal controls were considered as significant. (E) Bar graphs of array data for 
Amphiregulin (AREG), DKK-1, and EGFr at 0.05 mM, presented as ratio of control (Fold change) ± SD (n=2).
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proportional to total iron content and very likely, therefore, 
to be directly related (Figure 3B).
Next, we considered how cellular iron levels per 
se might influence amphiregulin at the molecular level. 
AREG mRNA does not contain iron responsive elements 
(IRE) and its translation is, therefore, not regulated by 
IRPs. Amphiregulin is a soluble protein produced by 
cleavage of an extracellular domain and, as such, it is 
regulated post-translationally. However, the cleavage of 
amphiregulin is mediated by different metalloproteinases 
such as ADAM17, which is regulated by O2 tension and 
HIF2, and the latter is related to iron influx in tumor cells 
[17]. However, cellular HIF2 levels were unchanged 
in response to the different iron supplements (data not 
shown), perhaps because IRPs have no IRE binding 
activity when intracellular iron levels are high and, in 
our assay, cells were not iron deficient. Notwithstanding, 
ADAM17 levels were unaffected in ferrous sulfate-treated 
cells (0.4 mM), versus no-added iron controls, but were 
significantly lower than for Ferric EDTA (0.05-0.2 mM) 
and ferric citrate (0.05 mM) treated cells (Figure 4). 
This supports the ideas that (a) only baseline levels of 
amphiregulin protein are expressed in cells incubated with 
ferrous sulfate (b) where iron-induced increases of cellular 
amphiregulin do occur, the relationship is with iron form, 
rather than iron levels per se and (c) there is a possible role 
for ADAM17 in the process, albeit in a HIF2-independent 
fashion.
Cell proliferation
We next considered whether the iron chelate-
induced increase in amphiregulin was related to cell 
proliferation. In the first 72 hours post-seeding, different 
iron concentrations did not have a growth-promoting 
or growth-inhibitory effect on Caco-2 cells (Figure 5A) 
or Hutu-80 cells (Figure 5B). There was a suggestion 
for slight growth inhibitory effect of ferric citrate at 
higher concentrations, particularly in the Hutu-80 
cells, and this could be an effect of the here observed 
higher bioavailability compared to ferrous sulfate and 
ferric EDTA (Figure 2) thereby ‘flooding’ the cell with 
potentially cytotoxic labile iron. However, this seemingly 
has no bearing on the cancer-promoting effect of ferric 
citrate, considering the results of prior murine studies 
[18] and, collectively, we conclude that amphiregulin 
regulation by chelated iron is unrelated to increased speed 
of cancer cell proliferation.
Figure 2: Cellular amphiregulin levels in human epithelial colorectal adenocarcinoma Caco-2 cells incubated with 
iron compounds. Quantative data measured with Thermo Scientific™ hAREG ELISA kit. Data are presented as means, n=3 ± SD. The 
significance of the differences is expressed as letters a-e where a: p=2,5E-7, b: p=2,4E-5, c: p=1,14E-10, d: p=9.9E-7, e: p=0.6. Differences of 
p <0.05 were considered as significant.
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Figure 3: Cellular Ferritin (A, B) and total iron levels (B) in Caco-2 cells incubated with the different iron compounds. (A) Cellular 
ferritin levels of cells incubated with ferric EDTA (0.05 mM) was lower than in cells incubated with ferrous sulfate (0.05 mM). Data are 
presented as means ± SD (n=3). (B) Cellular levels of total iron and the corresponding ferritin levels in cells incubated with ferric citrate 
and ferrous sulfate (2 mM). Data are presented as means ± SD (n=4).
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Ferric citrate and ferric EDTA promote 
activation of ERK
After establishing the induction of the EGFr 
substrate amphiregulin, we investigated the down-stream 
mechanism for activation of growth related pathways 
(see Supplementary Figure 1). Preliminary data suggest 
that the Wnt pathway might be down-regulated (by 
DKK-1; Figures 1A, 1C, 1D, 1E, 6D) and that the JAK/
STAT pathway might be inactive (high BAD levels; data 
not shown), however, we found activity in the MAP 
kinase pathway. ELISA and Western blot data showed 
that The MAP kinases ERK 1 and 2 were activated 
(phosphorylated) in the presence of the iron chelates ferric 
citrate and ferric EDTA (0.2-0.5 mM in Caco-2 cells; 
Figure 6A, and in Hutu-80 cells (1 mM); Figure 6B). Thus, 
the increases in amphiregulin levels were associated with 
increased cellular levels of phosphorylated ERK (Figure 
6A, 6B, 6C versus Figure 6D). Cells treated with high 
levels of ferrous sulfate (0.2-0.5 mM) did not respond with 
activation of ERK (Figure 6A) and even at supra-intestinal 
levels (1 mM) there was still only an insignificant trend to 
activate ERK (Figure 6C).
DISCUSSION
Soluble forms of iron are widely used, both as 
nutritional supplements and also as therapeutics, the 
latter being mainly as oral iron replacement therapy 
or phosphate binders for patients with renal disease [2, 
19]. The ingested dose for adults varies being, typically, 
up to 20 mg of iron for nutritional supplements, 30-120 
mg iron for therapeutic supplements and as much as 630 
mg iron for the purpose of phosphate binding [19]. The 
cellular work described here used soluble iron forms 
relevant to supplementation or phosphate binding, and 
iron doses that are anticipated to occur in the gut lumen 
following ingestion of this nutritional or therapeutic iron. 
The rationale behind our study is based on published data 
suggesting that soluble iron, particularly some forms 
of chelated ferric iron, increase tumorigenesis in the 
large bowel in murine studies [7, 9]. Here, we sought 
to investigate which mechanisms might be responsible 
for this observed effect on tumorigenesis, and if the 
effect is unique to the chelated iron forms used and thus 
varied depending on iron’s chemical speciation. In this 
respect, there is no in vivo evidence for ferrous iron salts 
being a risk factor for enhanced tumorigenesis in the 
intestine, only studies in mouse models where diets were 
supplemented with either ferric citrate or ferric EDTA 
(see introduction). Indeed, we discovered that the iron 
chelates ferric EDTA and ferric citrate elevated the levels 
of the growth factor amphiregulin at all concentrations 
investigated (0.05-2 mM iron). This result was in contrast 
to ferrous sulfate which did not significantly increase 
amphiregulin levels at any iron level studied (0-1 mM). 
This was despite iron getting into cells, and being 
processed to upregulate ferritin, in all cases. In addition, 
Figure 4: ADAM17 protein levels in human epithelial duodenum adenocarcinoma Caco-2 cells. The cells were incubated 
with ferric citrate, ferric EDTA, ferrous sulfate, or control cells with no additional iron to the growth medium. ADAM17 levels were 
measured with the Thermo Scientific™ hTACE ELISA kit. Data are expressed as means ± SD (n=3). The significance of the differences 
is expressed as letters a-d where a: p=0.029, b: p=0.026, c: p=0.028, d: p=0.04, e: p=0.08. Differences of p <0.05 were considered as 
significant.
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we found that ERK phosphorylation was induced in the 
presence of the iron chelates only, indicating that the MAP 
kinase pathway was activated.
Events preceding amphiregulin induction –does 
the form of iron matter?
The soluble active form of amphiregulin is 
produced by sequential proteolytic cleavage of its 
precursor ectodomain. There seem to be several mediators 
that can facilitate the cleavage and, among others, 
metalloproteinases (MMPs) have been suggested [20]. 
For example, the metalloproteinase ADAM17 has been 
associated with amphiregulin ectodomain cleavage [21]. In 
contrast to other EGFr ligands, amphiregulin is considered 
to be a low-affinity ligand to the EGF receptor [22]. 
Therefore, amphiregulin interaction with the receptor is 
less efficient than EGF or TGF alpha at negative feedback 
Figure 5: Confluence curves in the human epithelial colorectal adenocarcinoma cell line Caco-2 (A) and the human epithelial duodenum 
adenocarcinoma cell line Hutu-80 (B) with different iron compounds. Cells were treated for an average of 66 h with the indicated iron 
compounds in complete growth media containing 5% FBS. Data shown as area under the confluence curve for cells grown in media 
supplemented with each compound divided by the area under the curve for cells grown in un-supplemented media (i.e. media without any of 
the added iron compounds). Data are presented as mean with SD (n = 2 or 1 independent experiments with 3 replicates for each experiment).
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Figure 6: Phosphorylation of the MAP kinases ERK 1 and 2 in epithelial adenocarcinoma cells. (A) Total phospho-ERK 
1 and 2 levels in Caco-2 cells at iron levels that could be found in the human gut. Data are presented as Means ± SD (n=3) measured with 
instantOne™ phospho-ERK 1/2 assay. The significance of the differences is expressed as letters a-d where a: p=0.05, b: p=0.5, c: p=0.002, 
d: p=0.04. (B) Western blot data presented as a bar graph (n=2) ofphosphorylated ERK 1 and 2, respectively, in the human epithelia 
adenocarcinoma cell line Hutu-80 cells at slightly higher than normal gut concentration of iron (1 mM). (C) Total phospho-ERK 1 and 2 
levels in Caco-2 cells at slightly higher iron concentration. (D) Protein Array data of amphiregulin, EGFr, and DKK-1 levels at comparative 
iron concentrations are presented for the purpose of comparison to the phosphorylation (activation) of ERK.
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mechanisms such as downregulation and degradation of the 
receptor [23], so this is advantageous for cancer growth.
From the work reported here, amphiregulin 
induction appears to be a key event in the onset of the 
oncogenic MAP kinase pathway, driven by the ferric 
chelates investigated, but it is unlikely that iron per se 
induces the expression of amphiregulin, given the findings 
with ferrous sulfate. Our hypothesis as to why some forms 
of iron, such as these ferric chelates, may have a cancer 
promoting effect, is that ferric iron may be involved in the 
inducible cyclooxygenase (COX-2) pathway associated 
with inflammation. In colon cancer, PGE2 and EGF, 
products formed by the cyclooxygenase (COX-2) pathway, 
have been shown to induce amphiregulin production [24, 
25]. There seem to be two possibilities for ferric iron to 
enter the cyclooxygenase pathway: either that ferric iron 
is involved directly in the oxidation of arachidonic acid 
and/or that ferric iron elevates the production of COX-
2 and thereby promotes the conversion of arachidonic 
acid into prostaglandins (including PGE2) that might 
facilitate cancerous growth. In support of the idea that 
some forms of chelated ferric iron elevate COX-2 levels, 
or oxidize arachidonic acid directly, are studies showing 
that iron in the form of ferric nitrilotriacetate (FeNTA) 
increases the production of PGE2 (in rabbits) [26] and 
that oral administration of Deferiprone, which is a strong 
Fe (III) chelator, decreases levels of PGE2(in rats) [27]. 
The previous findings that ferric nitrilotriacetate-induced 
PGE2, and our findings that ferric citrate and ferric EDTA 
induced amphiregulin, suggest that certain ferric chelates 
may be pro-cancerous. Simple ferric salts would not be 
available to enter the cell, as they precipitate forming 
solid phase oxo-hydroxides at intestinal/cellular pHs, 
whilst there is no evidence in the literature that ferrous 
sulfate would have an impact on COX-2 levels or PGE2 
production which is supported by our study showing no 
effect on amphiregulin induction.
Radelescu et al. demonstrated that luminal iron 
(from ferric citrate added to the animal diets) strongly 
promoted tumorigenesis in a mouse model with a 
deletion of the tumor suppressor gene APC, which is a 
common mutation in colorectal cancers [14]. In addition, 
they investigated ferrous sulfate effects on a Wnt target 
protein, c-Myc [14], as well as, in another study with a 
Wnt reporter assay [13], on cell lines, with and without 
the APC gene. Overall, they found that ferrous sulfate 
amplified c-Myc protein levels in the non-functional APC 
cell lines. In our studies, ferrous sulfate did not induce the 
Wnt inhibitor DKK-1 in contrast to the two ferric chelates 
investigated, which supports the previous findings that 
cell proliferation may be mostly driven through the Wnt 
pathway in the presence of ferrous sulfate.
Finally, on this aspect of discussion, we note that 
whilst there is convincing evidence that certain ferric 
chelates are associated with pro-cancerous activity in 
animal models with nothing yet shown for ferrous iron 
salts in vivo, it is possible that this is simply explained 
by choice of murine diet compositions. Ferric citrate 
appears to be the iron fortificant mostly used (e.g. in diets 
TD80394 and AIN76A).
MATERIALS AND METHODS
Ferrous sulfate heptahydrate (FeSO4) and ferric 
EDTA sodium salt solution (NaFeEDTA) were purchased 
from Sigma Aldrich. Ferrous sulfate was dissolved in 
acidified ultrapure water to produce a stock solution 
([Fe]= 40 mM). Ferric EDTA solution (NaFeEDTA) was 
diluted in ultrapure water to produce a stock solution of 
40 mM Fe. A stock solution of ferric citrate (FeCitrate) 
[Fe]= 8 mM, was produced by adding citric acid to ferric 
chloride on a 1:1 (Fe:Citrate) molar ratio. The solubility of 
iron in the ferric citrate stock solution was determined to 
be 88.3 +/- 2.4 % (n=3) by ultrafiltration and ICP analysis, 
but the iron solubility in growth medium may be higher 
since the iron concentration is lower. All stock solutions 
were filter sterilised (0.22 μm).
Cell culture
Two different epithelial cancer cell lines were used: 
colorectal adenocarcinoma [Caco-2 (ATCC® HTB37) and 
duodenum adenocarcinoma [Hutu 80 (ATCC®HTB40)]. 
The cells were grown in an incubator at 37°C, 5% CO2 
and 95% air at a relative humidity of approximately 95%. 
The medium was changed every second day (except for 
weekends) and the cells were passaged at approximately 
80% confluence. The cells were grown in MEM (E15-825; 
PAA, Pasching, Austria) with 10% FBS supplemented 
with Normocin™ (100 μg/ml; Invivogen) and before/
during the experiments, the medium was supplemented 
with 5% FBS.
Cell experiments
Caco-2 (p.31-40) and Hutu-80 cells (p. not retrievable) 
were seeded in 12-well plates (Corning, San Fransisco, CA, 
USA) at 150 000 or 200 000 cells/well. The medium (MEM 
5% FBS) was supplemented with iron solutions (chelated 
iron was soluble), except for controls, at [Fe] between 0.05 
mM-2 mM. The supplemented medium was aspirated after 
48 hours of incubation and the cells were washed in PBS 
before lysis in RIPA buffer (Sigma Aldrich, Schnelldorf, 
Germany) containing Pierce phosphatase and protease 
inhibitors, EDTA-free (Thermoscinetific, Rockford, IL, US). 
Aliquots of cell lysates were analysed for ferritin (DRG, CA, 
US) and total protein (Pierce, Chicago, IL, USA)) according 
to the manufacturer’s protocols. Total Fe was measured by 
inductively coupled plasma mass spectrometry using an 
Agilent 8800 Triple Quadrupole (ICP-MS/MS) coupled 
with an Integrated Sample Introduction System (ISIS-DS; 
Agilent Technologies, Cheshire UK). Calibration standards 
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were matrix matched using pooled urine spiked with 50ppb 
to 5ppm iron. All samples, reference materials (Clinchchek 
and Seronorm) and calibration standards were diluted 20-
fold in a solution containing 0.005% Triton™X-100, 0.05% 
TMAH (tetramethyl ammonium hydroxide) and 5 ppb Ge, 
which was used as internal standard. A mixture of hydrogen 
and oxygen was used as a reaction gas for the removal of 
analytical interferences and the main isotope of iron on mass 
(56Fe) was used for quantification.
Proliferation assay
Working solutions of 2 mM Fe for each iron 
compound were prepared fresh on the day of the 
experiment by diluting the stock solutions of the different 
iron materials in complete cell growth medium (5% 
FBS). The 2mM working solutions were used in serial 
dilutions to achieve the 8 different iron concentrations 
for the proliferation assay (0.89, 0.49, 0.27, 0.15, 0.08, 
0.05, 0.026, 0.015 mM [Fe]) in 96-well ImageLock cell 
culture plates. Control wells containing only complete 
growth medium without any extra iron compounds added 
were also prepared. The cells were seeded at a density of 
10,000-20,000 cells/well and the plates were incubated in 
a Live Content Imaging Incubator (Incucyte ZOOM, Essen 
BioScience Ltd., UK). Images and confluence data were 
acquired every 3 hours for 66 hours (on average) post-
seeding. Within each experiment, each iron concentration 
was tested in triplicate wells and the experiments were 
carried out on two separate occasions for Caco-2 cells 
(n=2) and on two or one occasion for the Hutu-80 cells 
(n=2 for FeSO4 and n=1 for Fe Citrate and Fe EDTA).
Translation of in vitro [iron] into human dosing
The postprandial luminal concentration of ionisable 
iron after a standard meal containing 3.45 mg of iron has 
been reported as 10 μM [28], therefore, a supplemental single 
dose of 60-65 mg of Fe would correspond to almost 200 μM 
iron in the lumen whilst a dose of 600-650 mg Fe would 
correspond to almost 2 mM.
Proteome profiling
Proteome profiler™ antibody arrays (Human 
XL Oncology Array Kit; R&D systems, MN; USA) for 
parallel determination of the relative levels of 84 human 
cancer-related proteins were used. Pooled triplicates of cell 
lysates were loaded (90 or 105 μg of total protein) to the 
arrays and the procedure was repeated for 2-4 experiments 
carried out on separate occasions. Development of the 
chemiluminescent signal was done using a ChemiDoc 
XRS+ (Bio-rad) and the membranes incubated with 
control and treatments to be compared, were processed 
and developed simultaneously to avoid differences in 
signal strength dependent on exposure times.
ELISA
Phosphorylated ERK levels were measured with 
instantOne™ phospho-ERK 1/2 assay (Affymetrix, CA, 
USA) according to the instructions of the kit. 10 μl of 
cell lysates were loaded into each well and the measured 
A450 signal was normalized to protein content of each 
sample. Cellular ADAM17 and amphiregulin levels were 
measured with the Thermo Scientific™ Human Tace 
(ADAM17) Elisa kit and the Thermo Scientific™ Human 
Amphiregulin Elisa kit, respectively, according to the 
manufacturer’s instructions. ADAM17 and amphiregulin 
levels were normalized to the cellular protein content of 
each sample.
SDS PAGE and western blot
The cell lysates were diluted in Laemmli sample 
buffer with 2-mercaptoethanol and heated at 95 °C for 
5 min. Samples (20 μg protein) were loaded on TGX-
gels (Bio-rad) and run with Tris/glycine/SDS buffer at 
200 V. After electrophoresis, the separated proteins were 
blotted to PVDF membranes using the Trans-Blot Turbo 
system with pre-packed transfer packs and the 3-min 
protocol (Bio-rad). After that, the blots were incubated in 
blocking buffer (Sigma Aldrich, Schnelldorf, Germany) 
at room temperature for 1 h. The primary antibody (r-α-
human p-ERK; AF1018, R&D systems) was diluted in 
blocking buffer (0.2 μg/mL) and the membranes were 
incubated overnight at 4 °C. After washing, the blots 
were incubated with secondary antibody (0.5 μg/mL) and 
StrepTactin-HRP conjugate (1 μL/10 ml) for 1 h. After 
washing in PBS tween, the blots were added to a solution 
of luminol and peroxide buffer (Bio-rad) and the bands 
were detected by the ChemiDoc™ XRS+ system (Bio-
rad) and analyzed with the software Image Lab™ 3.0.1 
(Bio-rad).
Statistics
Where applicable, data are presented as means 
± SD (n=2-4). Ferritin, protein, ELISA, WB data were 
calculated using Microsoft® excel for Mac version 15.36. 
For the proliferation assay data, the plots of confluence 
(%) vs time (h) were obtained for each iron compound 
and concentration using the Incucyte ZOOM software. 
Then, the area under each confluence curve (AUC) was 
determined, using GraphPad Prism 7.0, and plotted 
against the concentration for each test compound or 
control. Data is shown as AUC for each iron compound 
normalised against that of the control, plotted against iron 
concentration in Log10 scale (i.e. complete growth medium 
without supplemental iron added). Changes in the protein 
array data were considered significant if reaching a signal 
threshold of 10% of internal control and fold changes 
greater than 2.
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CONCLUSION
Ferric citrate and ferric EDTA induced amphiregulin 
production and the activation of the MAP kinase ERK 
while the Wnt inhibitor DKK-1 levels were high, but 
ferrous sulfate did not significantly increase amphiregulin 
or DKK-1 protein at supplemental/therapeutic levels of 
iron. These events suggest that different forms of iron may 
impact intestinal tumorigenesis differently. The chelates 
ferric citrate and ferric EDTA induce the oncogenic growth 
factor amphiregulin (a positively associated risk factor 
with colorectal cancer) and it should now be determined 
whether the ferrous sulfate impact on Wnt pathways in 
vitro translates to an oncogenic risk in vivo.
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